savara to present new data from pivotal phase 3 impala-2 trial of molgramostim nebulizer solution (molgramostim) in patients with autoimmune pulmonary alveolar proteinosis (apap) at the european respiratory society (ers) congress 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced...